Data from phase I/II clinical trials demonstrated that recombinant PEGylated IL-10 alone shows some anti-tumor effects against multiple cancer types including renal carcinoma, melanoma, and breast cancer [19]. This evidence concerns the gene IL10 and neoplasm.